Mechanisms of diabetic kidney disease and established and emerging treatments

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Nature Reviews Endocrinology

• Publication date

  2025-09-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41574-025-01171-3PMID 40935879
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.

  2025cited by this paper
• Thrombomodulin: A key regulator of intravascular blood coagulation, fibrinolysis, and inflammation, and a treatment for disseminated intravascular coagulation

  2025cited by this paper
• Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants.

  2025cited by this paper
• Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression

  2024cited by this paper
• IL-6 and diabetic kidney disease

  2024cited by this paper
• Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study

  2024influential reference
• Multi‐organ single‐cell RNA sequencing in mice reveals early hyperglycemia responses that converge on fibroblast dysregulation

  2024cited by this paper
• Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.

  2024cited by this paper
• Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes.

  2024influential reference
• NAD^+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury

  2023cited by this paper
• Contribution of CKD to mortality in middle-aged and elderly people with diabetes: the China Health and Retirement Longitudinal Study

  2023cited by this paper
• Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention

  2023cited by this paper
• The Activation of cGAS-STING in Acute Kidney Injury

  2023cited by this paper
• The Mechanism of Hyperglycemia-Induced Renal Cell Injury in Diabetic Nephropathy Disease: An Update

  2023cited by this paper
• Endothelin Receptor Antagonists in Kidney Disease

  2023cited by this paper
• Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared to placebo.

  2023influential reference
• Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway

  2023influential reference
• Broadening horizons in mechanisms, management, and treatment of diabetic kidney disease.

  2023cited by this paper
• Associations Between Albuminuria and Mortality Among US Adults by Demographic and Comorbidity Factors

  2023cited by this paper
• Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.

  2023cited by this paper
• Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.

  2023cited by this paper
• Indicators of Kidney Fibrosis in Patients with Type 2 Diabetes and Chronic Kidney Disease Treated with Dulaglutide

  2023cited by this paper
• Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease

  2023cited by this paper
• The role of complement in kidney disease

  2023cited by this paper
• Update on Diabetic Kidney Disease (DKD): Focus on Non-Albuminuric DKD and Cardiovascular Risk

  2023cited by this paper
• Complement Deposition Predicts Worsening Kidney Function and Underlines the Clinical Significance of the 2010 Renal Pathology Society Classification of Diabetic Nephropathy

  2022cited by this paper
• Empagliflozin in Patients with Chronic Kidney Disease

  2022influential reference
• A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease

  2022influential reference
• Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?

  2022cited by this paper
• Differential and shared genetic effects on kidney function between diabetic and non-diabetic individuals

  2022cited by this paper
• Nutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases

  2022cited by this paper
• An Interim Analysis of Clinical and Histopathological Results of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study

  2022cited by this paper
• Association of Albuminuria and Regression of Chronic Kidney Disease in Adults With Newly Diagnosed Moderate to Severe Chronic Kidney Disease

  2022cited by this paper
• KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.

  2022cited by this paper
• Nephrons, podocytes and chronic kidney disease: Strategic antihypertensive therapy for renoprotection

  2022cited by this paper
• Update on Pathogenesis of Glomerular Hyperfiltration in Early Diabetic Kidney Disease

  2022cited by this paper
• Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

  2022influential reference
• MO399: Remodel: A Mechanistic Trial Evaluating the Effects of Semaglutide on the Kidneys In People With Type 2 Diabetes and Chronic Kidney Disease

  2022cited by this paper
• The Role of Hypoxia-Inducible Factor-1 Alpha in Renal Disease

  2022cited by this paper
• Hypoxia-Inducible Factors and Diabetic Kidney Disease—How Deep Can We Go?

  2022cited by this paper
• Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases

  2022cited by this paper
• Glomerular hyperfiltration

  2022cited by this paper
• The Epidemiology of Diabetic Kidney Disease

  2022cited by this paper
• Therapeutic Advances in Diabetic Nephropathy

  2022cited by this paper
• Cellular crosstalk of glomerular endothelial cells and podocytes in diabetic kidney disease

  2022cited by this paper
• NLRP3-mediated pyroptosis in diabetic nephropathy

  2022cited by this paper
• Circulating Thrombomodulin: Release Mechanisms, Measurements, and Levels in Diseases and Medical Procedures

  2022cited by this paper
• Mitochondrial Contribution to Inflammation in Diabetic Kidney Disease

  2022cited by this paper
• Molecular Signatures of Glomerular Neovascularization in a Patient with Diabetic Kidney Disease.

  2022cited by this paper
• Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy.

  2021cited by this paper
• The mineralocorticoid receptor in chronic kidney disease

  2021cited by this paper
• Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review

  2021influential reference
• Molecular Signatures of Diabetic Kidney Disease Hiding in a Patient with Hypertension-Related Kidney Disease.

  2021cited by this paper
• The Role of Glomerular Epithelial Injury in Kidney Function Decline in Patients With Diabetic Kidney Disease in the TRIDENT Cohort

  2021cited by this paper
• IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.

  2021cited by this paper
• Activation of complement C1q and C3 in glomeruli might accelerate the progression of diabetic nephropathy: Evidence from transcriptomic data and renal histopathology

  2021cited by this paper
• Recent Advances in Diabetic Kidney Diseases: From Kidney Injury to Kidney Fibrosis

  2021cited by this paper
• OUP accepted manuscript

  2021influential reference
• TGF-Beta as a Master Regulator of Diabetic Nephropathy

  2021cited by this paper
• Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.

  2021cited by this paper
• Hyperglycemia modulates M1/M2 macrophage polarization via reactive oxygen species overproduction in ligature-induced periodontitis.

  2021cited by this paper
• Treatment of Diabetic Kidney Disease: Current and Future

  2021cited by this paper
• Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers

  2021influential reference
• Ferroptosis Enhanced Diabetic Renal Tubular Injury via HIF-1α/HO-1 Pathway in db/db Mice

  2021cited by this paper
• High glomerular filtration rate is associated with impaired arterial stiffness and subendocardial viability ratio in prediabetic subjects.

  2021cited by this paper
• Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

  2021cited by this paper
• Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

  2021influential reference
• Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis

  2021cited by this paper
• Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists

  2021cited by this paper
• Single cell regulatory landscape of the mouse kidney highlights cellular differentiation programs and disease targets

  2021cited by this paper
• The role of inflammation in diabetic kidney disease

  2021cited by this paper
• Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC)

  2021cited by this paper
• Kidney disease genetic risk variants alter lysosomal beta-mannosidase (MANBA) expression and disease severity

  2021cited by this paper
• Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective

  2021cited by this paper
• Trajectories of kidney function in diabetes: a clinicopathological update

  2021cited by this paper
• Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK

  2021influential reference
• Modelling the Phosphorylation of Glucose by Human hexokinase I

  2021cited by this paper
• Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

  2021influential reference
• Seroprevalence of SARS-CoV-2 and Risk Assessment Among Healthcare Workers at a Dedicated Tertiary Care COVID-19 Hospital in Delhi, India: A Cohort Study

  2021cited by this paper
• Modeling the Glomerular Filtration Barrier and Intercellular Crosstalk

  2021cited by this paper
• Epigenetic Mechanisms in Diabetic Vascular Complications and Metabolic Memory: The 2020 Edwin Bierman Award Lecture

  2021cited by this paper
• Update on diagnosis, pathophysiology, and management of diabetic kidney disease

  2021cited by this paper
• Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

  2020influential reference
• Hypoxia-Inducible Factor and Oxygen Biology in the Kidney.

  2020cited by this paper
• Dapagliflozin in Patients with Chronic Kidney Disease.

  2020cited by this paper
• Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study.

  2020cited by this paper
• Transforming Growth Factor-Beta1 in Diabetic Kidney Disease

  2020cited by this paper
• Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.

  2020cited by this paper
• The Link Between the Mitochondrial Fatty Acid Oxidation Derangement and Kidney Injury

  2020cited by this paper
• Association of Glomerular Complement C4c Deposition With the Progression of Diabetic Kidney Disease in Patients With Type 2 Diabetes

  2020cited by this paper
• Nonproteinuric diabetic kidney disease

  2020cited by this paper
• Glyceraldehyde-3-phosphate Dehydrogenase Is a Multifaceted Therapeutic Target

  2020influential reference
• A Multimodal and Integrated Approach to Interrogate Human Kidney Biopsies with Rigor and Reproducibility: Guidelines from the Kidney Precision Medicine Project.

  2020cited by this paper
• The tubular hypothesis of nephron filtration and diabetic kidney disease

  2020cited by this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cited by this paper
• Molecular Mechanisms in Early Diabetic Kidney Disease: Glomerular Endothelial Cell Dysfunction

  2020cited by this paper
• Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets

  2020cited by this paper
• Discovery and prioritization of variants and genes for kidney function in >1.2 million individuals

  2020cited by this paper
• Role of actin cytoskeleton in podocytes

  2020cited by this paper
• High glucose-induced apoptosis and necroptosis in podocytes is regulated by UCHL1 via RIPK1/RIPK3 pathway.

  2019cited by this paper

• Correlation between serum prolactin and the systemic immune-inflammation index in diabetic kidney disease: a cross-sectional study

  2026cites this paper
• SIRT2 in Diabetic Kidney Disease: Multifaceted Regulatory Roles and Therapeutic Challenges

  2026cites this paper
• Shenxiao decoction ameliorates podocyte injury in diabetic nephropathy via upregulating RUNX3 expression and inhibiting the JAK2/STAT3 signaling pathway.

  2026cites this paper
• Imeglimin protects against acute kidney injury caused by transient ischemia.

  2026cites this paper
• Post-translational modifications in diabetic kidney disease (Review)

  2026cites this paper
• Molecular pathways and emerging therapeutic targets in the pathogenesis of diabetic kidney disease.

  2026cites this paper
• Aflatoxin B1 Accelerates Diabetic Nephropathy Progression via ITGA11/LTBP1-Dependent Oxidative and Fibrotic Pathways: Evidence from Multi-Omics and Molecular Simulations.

  2026cites this paper
• The Anti-Fibrotic Potential of GLP-1 and GIP Receptor Agonists in Chronic Inflammatory Disorders: Mechanisms and Therapeutic Horizons

  2026cites this paper
• Remnant cholesterol/high‐density lipoprotein cholesterol ratio is a new powerful tool for identifying diabetic kidney disease

  2026cites this paper
• Immune-metabolic interactions shape the fibrotic landscape of diabetic kidney disease: emerging mechanisms and therapeutic prospects

  2026cites this paper
• Tubules, Targets, and Translational Promise in Diabetic Kidney Disease.

  2026cites this paper
• Clinical profile and outcome of AA amyloidosis associated kidney disease in India

  2025cites this paper
• Urinary Branched-Chain Amino Acid Excretion and Chronic Kidney Disease Progression in Patients With Type 2 Diabetes.

  2025cites this paper
• Monocyte human leukocyte antigen-DR-mediated diabetic nephropathy progression is a promising therapeutic target

  2025cites this paper
• Sex-Specific Associations Between Metabolic Patterns and Renal Function Decline: A Retrospective Cohort Study in Southeastern China

  2025cites this paper
• Assessing Renoprotective Effects of Empagliflozin and Telmisartan Combination Therapy in Non-albuminuric Diabetic Nephropathy: A Retrospective Cohort Study

  2025cites this paper
• Promoting soluble guanylate cyclase activity via guanylate cyclase stimulators or guanylate cyclase activators: a feasible option in diabetic kidney disease.

  2025cites this paper